Share your research articles, interpretations and experiences here. Let us know how these studies affect you and your decisions.
Posted on: Jul 29, 2021 04:04PM
The DESTINY-Breast06 trial is enrolling people with metastatic hormone-receptor-positive breast cancer with low HER2 levels that has been previously treated with at least two hormonal therapies
The DESTINY-Breast06 trial is for people diagnosed with metastatic hormone-receptor-positive breast cancer with low HER2 levels that has been previously treated with at least two hormonal therapy medicines.
In this study, HER2-low breast cancer means the cancer has a score of 1+ or 2+ on an immunohistochemistry (IHC) HER test and/or a negative result on a in situ hybridization (ISH) HER2 test.
The trial wants to see if fam-trastuzumab-deruxtecan-nxki (brand name: Enhertu) allows people to live longer without the metastatic cancer growing or simply live longer overall, compared to people being treated with standard-of-care chemotherapy. The trial also will collect information on how the treatment affects people's quality of life.
Fam-trastuzumab-deruxtecan-nxki is given intravenously, which means the medicine is delivered directly into your bloodstream through an IV or a port. The medicine usually is given every 3 weeks unless the cancer grows or unacceptable side effects develop.
People are eligible for the DESTINY-Breast06 trial if:
The DESTINY-Breast06 trial is being conducted at multiple sites around the world and the United States. For a complete list of sites, visit https://clinicaltrials.gov/ct2/show/NCT04494425.
For more information on detailed eligibility requirements or to enroll https://www.breastcancer.org/treatment/clinical_trials/featured#destiny6)